Neues bei Kopfschmerzen 2004

Zusammenfassung

Neue wissenschaftliche Daten und Erkenntnisse zur Pathophysiologie und Genetik von Kopfschmerzerkrankungen haben zur Etablierung neuer Tiermodelle und zur Entwicklung neuer Substanzen zur Therapie und Prophylaxe beigetragen. Diese Übersicht fasst neue Erkenntnisse und Studien zu Kopfschmerzen und ihre Therapie zusammen.

Abstract

Recently new scientific data were gained regarding genetics and pathophysiology of headache disorders. Animal models were established and improved the development of new drugs for acute therapy and prophylaxis. This review summarises studies on headache published in 2003 and 2004.

Literatur

• 1 Headache Classification Committee of the International Headache Society . Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain.  Cephalalgia. 1988;  8, Suppl 7 1-93
• 2 Olesen J, Bousser M-G, Diener H. et al . The International Classification of Headache Disorders. 2^nd Edition.  Cephalalgia. 2004;  24, Suppl 1 1-160
• 3 Rasmussen B K. Epidemiology. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. New York; Raven Press 1993: 439-443
• 4 Ulrich V, Gervil M, Kyvik K O. et al . Evidence of a genetic factor in migraine with aura: a population-based danish twin study.  Ann Neurol. 1999;  45 242-246
• 5 Joutel A, Bousser M, Biousese V. et al . A gene for familial hemiplegic migraine maps to chromosome 19.  Nature Genetics. 1993;  5 40-45
• 6 Ophoff R A, Terwindt G M, Vergouwe M N. et al . Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca²⁺ channel gene CACNLA4.  Cell. 1996;  87 543-552
• 7 Fusco M De, Marconi R, Silvestri L. et al . Haploinsufficiency of ATP1A2 encoding the Na/K pump alpha2 subunit associated with familial hemiplegic migraine type 2.  Nature Genetics. 2003;  33 192-196
• 8 Ophoff R A, Terwindt G M, Frants R R. et al . P/Q-type Ca²⁺ channel defects in migraine, ataxia and epilepsy.  TiPS. 1998;  19 121-127
• 9 Moskowitz M, Bolay H, Dalkara T. Deciphering migraine mechanisms: clues from familial hemiplegic migraine genotypes.  Ann Neurol. 2004;  55 276-280
• 10 Vanmolkot K, Kors E, Hottenga J. et al . Novel mutations in the Na+, K+-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions.  Ann Neurol. 2003;  54 360-366
• 11 Thomsen L L, Ostergaard E, Olesen J. et al . Evidence for a separate type of migraine with aura: Sporadic hemiplegic migraine.  Neurology. 2003;  25 595-601
• 12 Terwindt G, Kors E, Haan J. et al . Mutation analysis of the CACNA1A calcium channel subunit gene in 27 patients with sporadic hemiplegic migraine.  Arch Neurol. 2002;  59 1016-1018
• 13 Terwindt G M, Ophoff R A, Haan J. et al . Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine.  Neurology. 1998;  50 1105-1110
• 14 Chapman K, Szczygielski B, Toth C. et al . Pseudomigraine with lymphocytic pleocytosis: a calcium channelopathy? Clinical description of 10 cases and genetic analysis of the familial hemiplegic migraine gene CACNA1A.  Headache. 2003;  43 892-895
• 15 Wang S, Fuh J, Lu S. et al . Migraine prevalence during menopausal transition.  Headache. 2003;  43 470-478
• 16 Winner P, Wasiewski W, Gladstein J. et al . Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria.  Headache. 1997;  37 545-548
• 17 Winner P, Rothner A, Putnam D. et al . Demographic and migraine characteristics of adolescents with migraine: Glaxo Wellcome clinical trials' database.  Headache. 2003;  43 451-457
• 18 Evans R, Lipton R, Silberstein S. The prevalence of migraine in neurologists.  Neurology. 2003;  61 1271-1272
• 19 Kruit M, Buchem M van, Hofman P. et al . Migraine as a risk factor for subclinical brain lesions.  JAMA. 2004;  291 427-434
• 20 Harno H, Hirvonen T, Kaunisto M. et al . Subclinical vestibulocerebellar dysfunction in migraine with and without aura.  Neurology. 2003;  61 1748-1752
• 21 Chang C L, Donaghy M, Poulter N. et al . Migraine and stroke in young women: case-control study.  BMJ. 1999;  318 13-18
• 22 Welch K MA, Bousser M-G. Migraine and stroke. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. 2^nd ed. Philadelphia; Lippincott Williams & Wilkins 2000: 529-542
• 23 Diener H, Welch K, Mohr J P. Migraine and stroke. In: Mohr J, Choi D, Grotta J, Wolf P (eds) Stroke. Pathophysiology, diagnosis and management. Philadelphia; Churchill Livingstone 2004
• 24 Donaghy M, Chang C L, Poulter N. et al . Duration, frequency, recency, and type of migraine and the risk of ischaemic stroke in women of childbearing age.  J Neurol Neurosurg Psychiatry. 2002;  73 747-750
• 25 Breslau N, Davis G C. Migraine, major depression and panic disorder: a prospective epidemiologic study of young adults.  Cephalalgia. 1992;  12 85-90
• 26 Breslau N, Schultz L R, Stewart W F. et al . Headache and major depression. Is the association specific to migraine?.  Neurology. 2000;  54 308-313
• 27 Bahra A, Goadsby P J. The comorbidity of migraine and depression: a review.  Neurology and Psychiatry. 1998;  2 23-27
• 28 Breslau N LR, Stewart W F, Schultz L R, Welch K M. Comorbidity of migraine and depression: Investigating potential etiology and prognosis.  Neurology. 2003;  60 1308-1312
• 29 Lipton R B, Silberstein S D. Neurologic and psychiatric comorbidity with migraine.  Neurology. 1994;  44 S1-S47
• 30 Leniger T, Diener H-C. Migräne und Komorbidität. In: Diener H-C (Hrsg) Kopfschmerzen. Stuttgart; Thieme 2003: 58-60
• 31 Sztajzel R, Genoud D, Roth S. et al . Patent foramen ovale, a possible cause of symptomatic migraine: a study of 74 patients with acute ischemic stroke.  Cerebrovasc Dis. 2002;  13 102-106
• 32 Carerj S, Narbone M, Zito C. et al . Prevalence of atrial septal aneurysm in patients with migraine: an echocardiographic study.  Headache. 2003;  43 725-728
• 33 Diener H-C, Hartung E, Chrubasik J. et al . A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study.  Cephalalgia. 2001;  21 140-144
• 34 Leniger T, Driesch S von den, Isbruch K. et al . Clinical characteristics of patients with comorbidity of migraine and epilepsy.  Headache. 2003;  43 672-677
• 35 Leniger T D, Diener H C, Hufnagel A. Erhöhte zerebrale Erregbarkeit und „spreading depression” Ursachen für eine Komorbidität von Epilepsie und Migräne?.  Nervenarzt. 2003;  74 869-874
• 36 The Diclofenac-K/Sumatriptan Migraine Study Group . Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal antiinflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo.  Cephalalgia. 1999;  19 232-240
• 37 Thomas H M, Kudrow D B, Ashford E. et al . A phase III multicentre, randomised, double-blind, parallel-group study of valdecoxib 40 mg vs placebo in patients with multiple moderate or severe acute migraine headaches with and without aura (abstract).  Cephalalgia. 2003;  23 697
• 38 Diener H-C, Reches A, Pascual J. et al . Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.  Europ Neurol. 2002;  47 99-107
• 39 The Multinational Oral Sumatriptan Cafergot Comparative Study Group . A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine.  Eur Neurol. 1991;  31 314-322
• 40 Charlesworth B, Dowson A, Purdy A. et al . Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.  CNS Drugs. 2003;  17 653-667
• 41 Göbel H, Boswell D, Winter P DO. et al .A comparison of the efficacy and tolerability of naratriptan and sumatriptan among migraineurs with a history of frequent (50 % of attacks) headache recurrence. Amsterdam; Poster, VIIIth IHS Congress 1997: 163-165
• 42 Sheftell F, O'Quinn S, Watson C. et al . Low migraine headache recurrence with naratriptan: clinical parameters related to recurrence.  Headache. 2000;  40 103-110
• 43 Tfelt-Hansen P, Teall J, Rodriguez F. et al . Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine.  Headache. 1998;  38 748-755
• 44 Goldstein J, Ryan R, Jiang K. et al . Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 and 50 mg in migraine.  Headache. 1998;  38 737-747
• 45 Tfelt-Hansen P, Ryan R E. Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials.  Neurology. 2000;  55, Suppl 2 S19-S24
• 46 Goadsby P J, Ferrari M D, Olesen J. et al . Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan.  Neurology. 2000;  54 156-163
• 47 Sandrini G, Färkkilä M, Burgess G. et al . Eletriptan vs sumatriptan. A double-blind, placebo-controlled, multiple migraine attack study.  Neurology. 2002;  59 1210-1217
• 48 Diener H, Ryan R, Sun W. et al . The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg.  Eur J Neurol. 2004;  11 125-134
• 49 Garcia-Ramos G, MacGregor E, Hilliard B. et al . Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine.  Cephalalgia. 2003;  23 869-876
• 50 Steiner T, Diener H, MacGregor E. et al . Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine.  Cephalalgia. 2003;  23 942-952
• 51 Pascual J, Falk R, Docekal R. et al . Tolerability and efficacy of almotriptan in the long-term treatment of migraine.  Eur Neurol. 2001;  45 206-213
• 52 Dowson A J, Massiou H, Lainez J M. et al . Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomised, double-blind, placebo-controlled clinical trial.  Cephalalgia. 2002;  22 453-461
• 53 Visser W H, Vriend R HM de, Jaspers N. et al . Sumatriptan - nonresponders: a survey in 366 migraine patients.  Headache. 1996;  36 471-475
• 54 Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against development of cutaneous allodynia.  Ann Neurol. 2004;  55 19-26
• 55 Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitization.  Ann Neurol. 2004;  55 27-36
• 56 Mathew N. Early intervention with almotriptan improves sustained pain-free response in acute migraine.  Headache. 2003;  43 1075-1079
• 57 Mathew N, Schoenen J, Winner P. et al . Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg.  Headache. 2003;  43 214-222
• 58 Färkkilä M, Olesen J, Dahlof C. et al . Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan.  Cephalalgia. 2003;  23 463-471
• 59 Chia Y, Lim S, Wang S. et al . Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatory drugs.  Headache. 2003;  43 984-990
• 60 Mathew N, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review.  Headache. 2003;  43 962-974
• 61 Christie S, Göbel H, Mateos V. et al . Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine.  Eur Neurol. 2002;  49 20-29
• 62 Baos V, Serrano A, Torrecilla M. et al . Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting.  Int J Clin Pract. 2003;  57 761-768
• 63 Schulman E, Dermott K. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs.  Headache. 2003;  43 729-733
• 64 The Subcutaneous Sumatriptan International Study Group . Treatment of migraine attacks with sumatriptan.  N Engl J Med. 1991;  325 316-321
• 65 Diener H-C. for the ASASUMAMIG Study Group . Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study.  Cephalalgia. 1999;  19 581-588
• 66 Stillman M, Zajac D, Rybicki L. Treatment of primary headache disorders with intravenous valproate: initial outpatient experience.  Headache. 2004;  44 65-69
• 67 Goadsby P J, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache.  Ann Neurol. 1990;  28 183-187
• 68 Doods H, Hallermayer G, Wu D. et al . Pharmacological profil of BIBN4096BS, the first selective small molecule CGRP antagonist.  Br J Pharmacol. 2000;  129 420-423
• 69 Olesen J, Diener H, Husstedt I W. et al . Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks.  N Engl J Med. 2004;  350 1104-1110
• 70 Eikermann A D, Diener H C. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine.  Cephalalgia. 2003;  23 344-347
• 71 Reuter U, Sanchez Del Rio M, Carpay J. et al . Placebo adverse events in headache trials: headache as an adverse event of placebo.  Cephalalgia. 2003;  23 496-503
• 72 Diener H-C. und die Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg) .Leitlinien für Diagnostik und Therapie in der Neurologie. 2. ed. Stuttgart; Thieme 2003
• 73 Brandes J, Saper J, Diamond M. et al . Topiramate for migraine prevention: a randomized controlled trial.  JAMA. 2004;  291 965-973
• 74 Martinez H, Londono O, Cantu-Martinez L. et al . Topiramate as an adjunctive treatment in migraine prophylaxis.  Headache. 2003;  43 1080-1084
• 75 Silvestrini M, Bartolini M, Coccia M. et al . Topiramate in the treatment of chronic migraine.  Cephalalgia. 2003;  23 820-824
• 76 Tronvik E, Stovner L, Helde G. et al . Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.  JAMA. 2003;  289 65-69
• 77 Gallai V, Alberti A, Rossi C. et al . An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine.  J Headache Pain. 2003;  4 92-96
• 78 Koseoglu E, Akboyraz A, Soyuer A. et al . Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura.  Cephalalgia. 2003;  23 972-976
• 79 Matharu M, Bartsch T, Ward N. et al . Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study.  Brain. 2003;  127 220-230
• 80 Zagami A S. Chronic tension-type headache - rational drug treatment options.  CNS Drugs. 1995;  4 90-98
• 81 Fogelholm R, Murros K. Tizanidine in chronic tension-type headache: A placebo controlled double-blind cross-over study.  Headache. 1992;  32 509-513
• 82 Murros K, Kataja M, Hedman C. et al . Modified-release formulation of tizanidine in chronic tension-type headache.  Headache. 2000;  40 633-637
• 83 Shimomura T, Awaki E, Kowa H. et al . Treatment of tension-type headache with tizanidine hydrochloride: Its efficacy and relationship to the plasma MHPG concentration.  Headache. 1991;  31 601-604
• 84 Holroyd K, Labus J, O'Donnell F. et al . Treating chronic tension-type headache not responding to amitriptyline hydrochloride with paroxetine hydrochloride: a pilot evaluation.  Headache. 2003;  43 999-1004
• 85 Bendtsen L, Jensen R, Olesen J. A non-selective (amitriptyline), but no a selective (citalopram), serotonin reuptake inhibitor is effective in the prophylactic treatment of chronic tension-type headache.  J Neurol Neurosurg Psychiatry. 1996;  61 285-290
• 86 Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study.  Cephalalgia. 2004;  24 29-36
• 87 Bahra A, May A, Goadsby P J. Cluster headache: a prospective clinical study with diagnostic implications.  Neurology. 2002;  58 354-361
• 88 Ekbom K, Monstad I, Prusinski A. et al . Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study.  Acta neurol Scand. 1993;  88 63-69
• 89 Limmroth V, May A, Diener H-C. Der Stellenwert von Sumatriptan in der Anfallstherapie der Migräne und des Clusterkopfschmerzes.  Nervenheilkunde. 1996;  15 100-108
• 90 Vliet J A Van, Bahra A, Martin V. et al . Intranasal sumatriptan in cluster headache: Randomized placebo-controlled double-blind study.  Neurology. 2003;  60 630-633
• 91 Lainez M, Pascual J, Pascual A. et al . Topiramate in the prophylactic treatment of cluster headache.  Headache. 2003;  43 784-789
• 92 Leone M, Dodick D, Rigamonti A. et al . Topiramate in cluster headache prophylaxis: an open trial.  Cephalalgia. 2003;  23 1001-1002
• 93 Mulder L J, Spierings E L. Naratriptan in the preventive treatment of cluster headache.  Cephalalgia. 2002;  22 815-817
• 94 May A, Goadsby P J. Neuroimaging of cluster headache. In: Olesen J, Tfelt-Hansen P, Welch KMA (eds) The Headaches. 2^nd ed. Philadelphia; Lippincott Williams & Wilkins 2000: 703-708
• 95 May A, Bahra A, Büchel C. et al . PET and MRA findings in cluster headache and MRA in experimental pain.  Neurology. 2000;  55 1328-1335
• 96 May A, Bahra A, Buchel C. et al . Hypothalamic activation in cluster headache attacks.  Lancet. 1998;  352 275-278
• 97 Sprenger T, Bocker H, Tolle T R. et al . Specific hypothalamic activation during a spontaneuos cluster headache attack.  Neurology. 2004;  62 516-517
• 98 Franzini A, Ferroli P, Leone M. et al . Stimulation of the posterior hypothalamus for treatment of chronic intractable cluster headaches: first reported series.  Neurosurgery. 2003;  52 1095-1101
• 99 Leone M, Franzini A, D'Amico D. et al . Stereotactic electrode implant in inferior posterior hypothalamic gray matter to relieve intractable chronic cluster headache: the first reported case.  Neurology. 2001;  56, Suppl 3 A218
• 100 Leone M, Franzini A, Broggi G. et al . Hypothalamic deep brain stimulation for intractable chronic cluster headache: a 3-year follow up.  J Neurol Sci. 2003;  24, Suppl 2 143-145
• 101 Dichgans J, Diener H-C, Gerber W D. et al . Analgetika-induzierter Dauerkopfschmerz.  Dtsch med Wschr. 1984;  109 369-373
• 102 Katsarava Z, Fritsche G, Muessig M. et al . Clinical features of withdrawal headache following overuse of triptans and other headache drugs.  Neurology. 2001;  57 1694-1698
• 103 Limmroth V, Katsarava Z, Fritsche G. et al . Features of medication overuse headache following overuse of different acute headache drugs.  Neurology. 2002;  59 1011-1014
• 104 Rozen T. Melatonin as treatment for idiopathic stabbing headache.  Neurology. 2003;  61 865-866
• 105 Dodick D W, Mosek A C, Campbell J K. The hypnic („alarm clock”) headache syndrome.  Cephalalgia. 1998;  18 152-156
• 106 Raskin N H. The hypnic headache syndrome.  Headache. 1988;  28 534-536
• 107 Sibon I, Ghorayeb I, Henry P. Successful treatment of hypnic headache syndrome with acetazolamide.  Neurology. 2003;  61 1157-1158
• 108 Higgins J, Cousins C, Owler B. et al . Idiopathic intracranial hypertension: 12 cases treated by venous sinus stenting.  J Neurol Neurosurg Psychiatry. 2003;  74 1662-1666